|
Market Closed -
Other stock markets
|
After hours 08:00:00 | |||
| 150.73 USD | -1.08% |
|
150.49 | -0.16% |
| 06-18 | AbbVie's migraine drug meets main goal of late-stage study | RE |
| 06-17 | Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May | MT |
| Capitalization | 363B 315B 296B 269B 496B 31,341B 556B 3,479B 1,344B 14,336B 1,361B 1,332B 52,442B | P/E ratio 2025 * |
14.4x | P/E ratio 2026 * | 16.2x |
|---|---|---|---|---|---|
| Enterprise value | 367B 319B 300B 272B 502B 31,715B 563B 3,520B 1,360B 14,508B 1,377B 1,348B 53,068B | EV / Sales 2025 * |
4.02x | EV / Sales 2026 * | 3.75x |
| Free-Float |
77.08% | Yield 2025 * |
3.47% | Yield 2026 * | 3.57% |
More valuation ratios
* Estimated data
More news
Last Transcript: Johnson & Johnson
More recommendations
More press releases
More news
| 1 day | -0.16% | ||
| 1 week | -2.92% | ||
| Current month | -2.89% | ||
| 1 month | -0.40% | ||
| 3 months | -8.23% | ||
| 6 months | +4.13% | ||
| Current year | +4.22% |
| 1 week | 150.71 |  | 157.67 |
| 1 month | 150.71 | | 157.67 |
| Current year | 140.68 | | 169.99 |
| 1 year | 140.68 | | 169.99 |
| 3 years | 140.68 | | 183.35 |
| 5 years | 133.65 | | 186.69 |
| 10 years | 81.79 | | 186.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 62 | 03/01/2022 |
Joseph Wolk
DFI | Director of Finance/CFO | 58 | 01/07/2018 |
Penny M. Heaton
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Anne Mulcahy
BRD | Director/Board Member | 71 | 23/10/2009 |
Mark McClellan
BRD | Director/Board Member | 61 | 15/10/2013 |
Mary Beckerle
BRD | Director/Board Member | 70 | 09/06/2015 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 14.01% | 378 M€ | -1.30% | - | |
| 12.91% | 21 M€ | +0.30% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.08% | -2.92% | +3.49% | -11.05% | 363B | ||
| -0.78% | -2.92% | -11.94% | +169.86% | 705B | ||
| +0.07% | -7.39% | -51.14% | +26.32% | 331B | ||
| +0.01% | -3.14% | +8.25% | +34.14% | 328B | ||
| -0.68% | -5.69% | +2.92% | -15.57% | 254B | ||
| -0.17% | -3.36% | +0.91% | +19.00% | 228B | ||
| -0.28% | -4.75% | -14.86% | +4.50% | 220B | ||
| +1.29% | -1.28% | -38.05% | -6.30% | 199B | ||
| -0.19% | -0.79% | -5.39% | +23.34% | 156B | ||
| -0.50% | -2.45% | -12.88% | -48.68% | 136B | ||
| Average | +0.12% | -2.88% | -11.87% | +19.56% | 291.92B | |
| Weighted average by Cap. | +0.05% | -2.92% | -11.60% | +45.47% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 91.3B 79.26B 74.59B 67.77B 125B 7,890B 140B 876B 338B 3,609B 343B 335B 13,201B | 95.03B 82.51B 77.64B 70.54B 130B 8,213B 146B 912B 352B 3,757B 357B 349B 13,742B |
| Net income | 22.86B 19.85B 18.68B 16.97B 31.29B 1,976B 35.06B 219B 84.76B 904B 85.79B 83.97B 3,306B | 22.2B 19.27B 18.14B 16.48B 30.37B 1,918B 34.04B 213B 82.29B 877B 83.29B 81.53B 3,210B |
| Net Debt | 4.33B 3.76B 3.54B 3.21B 5.92B 374B 6.64B 41.53B 16.05B 171B 16.24B 15.9B 626B | -6.45B -5.6B -5.27B -4.79B -8.83B -557B -9.89B -61.88B -23.91B -255B -24.21B -23.69B -933B |
More financial data
* Estimated data
Employees
138,100
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/25 | 150.73 $ | -1.08% | 8,325,237 |
| 17/06/25 | 152.38 $ | -1.83% | 6,407,098 |
| 16/06/25 | 155.22 $ | -1.20% | 7,023,995 |
| 13/06/25 | 157.10 $ | +0.28% | 6,587,849 |
| 12/06/25 | 156.66 $ | +0.90% | 7,075,511 |
Delayed Quote Nyse, June 19, 2025 at 04:10 am
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
150.73USD
Average target price
169.18USD
Spread / Average Target
+12.24%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JNJ Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition